Validity of Plasma Neuropeptide Y in Combination with Clinical Factors in Predicting Neuralgia Following Herpes Zoster
Dan Wu,Fang Li,Feifei Yang,Jun Liu
DOI: https://doi.org/10.2147/ijgm.s480411
IF: 2.145
2024-10-19
International Journal of General Medicine
Abstract:Dan Wu, 1 Fang Li, 2 Feifei Yang, 3 Jun Liu 4 1 Department of Dermatology, Peking University First Hospital Ningxia Women and Children's Hospital (Ningxia Hui Autonomous Region Maternal and Child Health Hospital), Yinchuan City, Ningxia Hui Autonomous Region, 750011, People's Republic of China; 2 Department of Pathology, Peking University First Hospital Ningxia Women and Children's Hospital (Ningxia Hui Autonomous Region Maternal and Child Health Hospital), Yinchuan City, Ningxia Hui Autonomous Region, 750011, People's Republic of China; 3 Department of Dermatology, Tongzhou Maternal & Child Health Hospital of Beijing, Beijing City, 101101, People's Republic of China; 4 Department of Critical Care Medicine, the First People's Hospital of Yinchuan, Yinchuan City, Ningxia Hui Autonomous Region, 750001, People's Republic of China Correspondence: Jun Liu, Department of Critical Care Medicine, the First People's Hospital of Yinchuan, No. 2 Liqun West Street, Xingqing District, Yinchuan City, Ningxia Hui Autonomous Region, 750001, People's Republic of China, Email Background: Numerous lines of evidence suggest that neuropeptide Y (NPY) is critically involved in the modulation of neuropathic pain. Postherpetic neuralgia (PHN) is characterized by prolonged duration, severe pain, and significant treatment resistance, substantially impairing patients' quality of life. This study aims to evaluate the potential of plasma NPY levels in patients with PHN as a predictive biomarker for the development of this condition. Methods: Between February 2022 and December 2023, 182 patients with herpes zoster (HZ) were recruited. Thirty-eight volunteers with no history of HZ were also recruited as controls. Clinical factors, NPY, brain-derived neurotrophic factor (BDNF), and nerve growth factor (NGF) were assessed within 3 days of healing. Logistic regression analysis was used to predict the development of PHN. Results: NPY levels were lower and BDNF and NGF were higher in HZ patients than those in controls. Only NPY levels were lower in patients with PHN (n = 59) compared with those without PHN (n = 123). Age, acute pain severity, and rash area were independent predictors of PHN, as were NPY levels. The area under the curve (AUC) to predict the development of PHN based on the combination of NPY levels and clinical factors was 0.873 (95% CI: 0.805 to 0.940), and the AUC was 0.804 based on only clinical factors (AUC: 0.804, 95% CI: 0.728 to 0.881). Conclusion: Low plasma NPY levels are a predictor of developing PHN in patients with HZ. Combining clinical predictors with NPY levels may improve predictive accuracy. Keywords: neuropeptide Y, herpes zoster, postherpetic neuralgia, sensory neurons Herpes zoster (HZ) is caused by reactivated varicella-zoster virus infection of sensory ganglia and peripheral nerves and is characterized by pain and rash. 1 HZ is classified as acute in the first 30 days after the onset of the rash, sub-acute in the subsequent 30 to 90 days, and post-acute within 90 days. 2 Postherpetic neuralgia (PHN) is the most common chronic complication of HZ, with a prevalence rate of 9–34%, and it increases as age increases (68% of patients are ≥ 50 years of age). 3 PHN manifests different patterns of sensory dysfunction and both spontaneous and stimulus-induced pain, with these altered sensations potentially persisting long after the HZ rash has healed. 4 There is no monotherapy that improves all pain or abnormality. Thus, PHN prevention involves antiviral drugs and aggressive interventional pain management during acute stages of HZ. 5 There are three contributing factors to the development of PHN: inflammation, viral damage, and atrophy of the spinal dorsal horn. 6 With regard to PHN, Devor proposed the ectopic pacemaker hypothesis, which suggests that spontaneous pain and tactile anomalous pain in the peripheral nervous system are caused by ectopic impulses in damaged nerve fibres. Neuropeptide Y (NPY) is a 36-amino-acid peptide in the pancreatic peptide family and is considered to be one of the major neural signaling pathways. 7 It has been controversial whether NPY acts to promote or inhibit injury perception. In light of this, it appears that the different roles of this peptide depend on how it is delivered. 8 It has been reported that NPY binds to receptors in the periphery and plays a role in promoting injury perception. As a result of sciatic nerve injury, peptides or Y2R agonists exacerbate mechanical and thermal sensory sensitization, while Y1R agonists affect mechanical sensory sensitization but reverse thermal sensory sensitization. 9 In addition, a -Abstract Truncated-
medicine, general & internal